ANNE TSAO to Neoplasm Staging
This is a "connection" page, showing publications ANNE TSAO has written about Neoplasm Staging.
Connection Strength
0.384
-
Updates in Local-Regionally Advanced Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:553-562.
Score: 0.055
-
Current readings: Window-of-opportunity trials for thoracic malignancies. Semin Thorac Cardiovasc Surg. 2014; 26(4):323-30.
Score: 0.041
-
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol. 2012 Nov; 7(11):1645-52.
Score: 0.035
-
Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-?) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer. Clin Lung Cancer. 2011 Nov; 12(6):369-74.
Score: 0.032
-
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther. 2007 Jul; 6(7):1962-72.
Score: 0.024
-
Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2006 Sep 01; 24(25):4163-9.
Score: 0.023
-
Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg. 2005 Dec; 80(6):1988-92; discussion 1992-3.
Score: 0.022
-
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. 2023 09 09; 402(10405):871-881.
Score: 0.018
-
Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022 11; 164(5):1327-1337.
Score: 0.017
-
Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab. Clin Lung Cancer. 2021 05; 22(3):e451-e465.
Score: 0.015
-
A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 07 15; 26(14):3525-3536.
Score: 0.015
-
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer. 2018 06; 120:62-69.
Score: 0.013
-
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. Lung Cancer. 2017 10; 112:181-187.
Score: 0.012
-
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2015 Apr; 16(4):447-56.
Score: 0.010
-
Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res. 2013 Dec 15; 19(24):6967-75.
Score: 0.009
-
Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J Thorac Oncol. 2013 Apr; 8(4):436-42.
Score: 0.009
-
Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013 Feb; 8(2):238-45.
Score: 0.009
-
The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. Ann Thorac Surg. 2012 Sep; 94(3):914-20.
Score: 0.009
-
Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol. 2011 Nov; 6(11):1938-45.
Score: 0.008
-
Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. 2011 Oct 15; 117(20):4707-13.
Score: 0.008